Vitamin D Deficiency Linked to Severity of Chronic Plaque Psoriasis
The 25hydroxyvitamin D (25[OH] D) level in patients with plaque psoriasis compared with healthy control individuals is investigated.
Home
American Indians, Alaska Natives Engage in Few Skin Cancer Prevention Behaviors
Researchers at Brigham and Women’s Hospital investigated the skin cancer prevention behaviors of these rarely studied ethnic groups.
OAC in Patients With AF and COVID-19 Lowers Rates of Death, Thrombotic Events
Researchers assessed the relationship between oral anticoagulation for patients with COVID-19 and AF and incidence of in-hospital thrombotic events and death.
Funding Substance Use Treatment via Medicaid Fee-For-Service May Increase Access
Researchers examined the association between changes in Medicaid managed care plan coverage for substance use services and admissions for substance use treatment.
Infections Reported After Single Dose of Monkeypox Vaccine
Most cases of monkeypox that occur after vaccination with the modified Vaccinia Ankara-Bavarian Nordic vaccine (MVA-BN) occur within 14 days of receipt of the first dose.
Apremilast May Offer Cardiometabolic Benefit for Patients With Psoriasis
For patients with moderate-to-severe psoriasis, apremilast appears to have a neutral association with aortic vascular inflammation, generally beneficial associations with certain cardiometabolic biomarkers, and associations with reductions in visceral and subcutaneous fat.
Guideline Developed for Assessing Penicillin Allergies
Recommendations are presented for clinicians not trained in allergy or immunology who wish to develop a penicillin allergy de-labeling service in a hospital setting.
Guidance Issued for Assessing Bleeding Disorders When Child Abuse Suspected
Recommendations are presented to help guide pediatricians and other clinicians in the assessment of bleeding disorders when child abuse is suspected.
Few Patients With Alopecia Areata Are Willing to Undergo Treatment
The preferences of patients with alopecia areata and characteristics that would make treatment widely acceptable are described.
Tralokinumab Promising for Long-Term Treatment of Atopic Dermatitis
The safety and efficacy of up to 2 years tralokinumab treatment in a post hoc interim analysis is reported.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Dermatitis
Loading... 
Loading...